Table 2 Table showing relationship between cell cycle arrests with some of the known proteasome inhibitors in different cancer types
From: Therapeutic targeting of cancer cell cycle using proteasome inhibitors
Proteasome Inhibitor | Cancer Type | Cell cycle phase arrest | Proteins/ Pathways involved |
|---|---|---|---|
Bortezomib | Colorectal caner [8] | G2/M | UBE2C, cyclin A and cyclin B1 |
| Â | Malignant pleural mesothelioma (MPM), Breast cancer [51] | G2/M | p21 |
CML [42] | G2/M | Rb, NF-ĸB | |
Glioblatoma multiforme (GBM) [28] | G2/M | JNK, Cyclin B, p21, p27, CDK2, CDK4 and E2F4 | |
MG-132 | Lung cancer (Calu 6) [46] | S | ROS generation and GSH depletion |
Cervical cancer [55] | G2/M | ROS generation and GSH depletion | |
| Â | Gastric cancer [47] | G2/M | Macroautophagy |
Sanggenon C | Leukemia [13] | G0/G1 | p27 |
Isothiocyanates | Multiple myeloma [12] | G2/M | p53, IĸB, ROS generation |
BSc2118 | Multiple myeloma [11] | G2/M | p21, NF-ĸB |
Celastrol | Cervical cancer [62] | G2/M | Autophagy and paraptosis |